Hata H, Matsuzaki H
Second Department of Internal Medicine, Kumamoto University School of Medicine.
Nihon Rinsho. 1995 Mar;53(3):580-5.
Tumor cells in multiple myeloma are considered to originate from terminally differentiated B-cells e. g. plasma cells. Although it is known that antigens on circulating B-cells, such as CD20, are lost during terminal B-cell differentiation, antigens which are acquired on plasma cells are not well known. Plasma cell specific antibodies would provide useful informations of B-cell differentiation and diagnosis of myeloma. Moreover, therapeutic applications of these antibodies are already reported, especially, in bone marrow transplantation. On the other hand, phenotypic heterogeneity of myeloma cells is investigated by analyzing various antigens on myeloma cells. Monoclonal antibodies against myeloma cells which have appeared in the literature and their clinical applications are summarized.
多发性骨髓瘤中的肿瘤细胞被认为起源于终末分化的B细胞，例如浆细胞。尽管已知循环B细胞上的抗原，如CD20，在B细胞终末分化过程中会丢失，但浆细胞上获得的抗原尚不清楚。浆细胞特异性抗体将为B细胞分化和骨髓瘤诊断提供有用信息。此外，这些抗体的治疗应用已有报道，尤其是在骨髓移植方面。另一方面，通过分析骨髓瘤细胞上的各种抗原，研究了骨髓瘤细胞的表型异质性。总结了文献中出现的针对骨髓瘤细胞的单克隆抗体及其临床应用。
